Telomerase inhibition, telomere shortening, and decreased cell proliferation by cell permeable 2′-O-methoxyethyl oligonucleotides

Journal of Medicinal Chemistry

Volumn 45, Issue 25, 2002, Pages 5423-5425

  Chen, Zhi ^a,b   Monia, Brett P ^a,b   Corey, David R ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISIS 125625; ISIS 24691; ISIS 263924; OLIGONUCLEOTIDE; RNA; TELOMERASE; ZC 1;

ARTICLE; CELL MEMBRANE PERMEABILITY; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MALE; TELOMERE;

CELL DIVISION; CELL MEMBRANE PERMEABILITY; ENZYME INHIBITORS; HUMANS; OLIGONUCLEOTIDES; STRUCTURE-ACTIVITY RELATIONSHIP; TELOMERASE; TUMOR CELLS, CULTURED;

EID: 0037028047     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm025563v     Document Type: Article

References (24)

1. Braasch, D. A.; Corey, D. R. Novel antisense and peptide nucleic acid strategies for controlling gene expression. Biochemistry 2002, 41, 4503-4510.
2. Morin, G. B. The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats. Cell 1989, 59, 521-529.
3. Bearss, D. J.; Hurley, L. H.; Von Hoff, D. D. Telomere maintenance mechanisms as a target for drug development. Oncogene 2002, 19, 6632-6641.
4. Harley, C. B.; Futcher, A. B.; Greider, C. W. Telomeres shorten during ageing of human fibroblasts. Nature 1990, 35, 458-460.
5. Hastie, N. D.; Dempster M.; Dunlop, M. G.; Thompson A. M.; Green, D. K.; Allshire, R. C. Telomere reduction in human colorectal carcinoma and with ageing. Nature 1990, 346, 866-868.
6. Sun, D.; Thompson, B.; Cathers, B. E.; Salazar, M.; Kerwin, S. M.; Trent, J. O.; Jenkins, T. C.; Neidle, S.; Hurley, L. H. Inhibition of human telomerase by a G-quadruplex-interactive compound. J. Med. Chem. 1997, 40, 2113-2116.
7. Read, M.; Harrison, R. J.; Romagnoli, B.; Tanious, F. A.; Gowan, S. H.; Reszka, A. P.; Wilson, W. D.; Kelland, L. R.; Neidle, S. Structure-based design of selective and potent G quadruplex-mediated telomerase inhibitors. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 4844-4849.
8. Riou, J. F.; Guitat, L.; Mailliet, P.; Laoui, A.; Renou, E.; Petitegenet, O.; Megnin-Chanet, F.; Helene, C.; Mergny, J. L. Cell senescence and telomere shortening induced by a new series of specific G-quadruplex DNA ligands. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 2672-2677.
9. Damm, K.; Hemmann, U.; Garin-Chesa, P.; Hauel, N.; Kaufffman, I.; Priepke, H.; Niestroj, C.; Daiber, C.; Enenkel, B.; Guilliard, B.; Lauritsch, I.; Muller, E.; Pascolo, E.; Sauter, G.; Pantic, M.; Martens, U. M.; Wenz, C.; Lingner, J.; Kraut, N.; Rettig, W. J.; Schnapp, A. A highly selective telomerase inhibitor limiting cell proliferation. EMBO J. 2001, 20, 6958-6968.
10. Pascolo, E.; Wenz, C.; Lingner, J.; Hauel, N.; Priepke, H.; Kauffmann, I.; Garin-Chesa, P.; Rettig, W. J.; Damm, K.; Schnapp, A. Mechanism of human telomerase inhibition by BIBR1532, a synthetic, non-nucleosidic drug candidate. J. Biol. Chem. 2002, 277, 15566-15572.
11. Corey, D. R. Telomerase inhibition, oligonucleotides, and clinical trials. Oncogene 2002, 21, 631-637.
12. Norton, J. C.; Piatyszek, M. A.; Wright, W. E.; Shay, J. W.; Corey, D. R. Inhibition of human telomerase by peptide nucleic acids. Nat. Biotechnol. 1996, 14, 615-620.
13. Herbert, B.-S.; Pitts, A. E.; Baker, S. E.; Hamilton, S. E.; Wright, W. E.; Shay, J. W.; Corey, D. R. Inhibition of human telomerase leads to progressive telomere shortening and cell death. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 14726-14781.
14. Elayadi, A.; Demieville, A.; Wancewicz, E. V.; Monia, B. P.; Corey, D. R. Inhibition of telomerase by 2′-O-(2-methoxyethyl)-RNA oligomers: Effect of length, phosphorothioate substitution, and time inside cells. Nucleic Acids Res. 2001, 29, 1683-1689.
15. Gryaznov, S.; Pongracz, K.; Matray, T.; Schultz, T.; Pruzan, R.; Aimi, J.; Chin, A.; Harley, C.; Shea-Herbert, B.; Shay, J.; Oshima, Y.; Asai, A.; Yamashita, Y. Telomerase inhibitors-oligonucleotide phosphoramidates as potential therapeutic agents. Nucleosides Nucleotides 2001, 20, 401-410.
16. Herbert, B.-S.; Pongraz, K.; Shay, J. W.; Gryaznov, S. M. Oligonucleotide N3′-P5′ phosphoramidates as efficient telomerase inhibitors. Oncogene 2002, 21, 638-642.
17. Baker, B. F.; Condon, T. P.; Koller, E.; McKay, R. A.; Siwkowski, A. M.; Vickers, T. A.; Monia, B. P. Discovery and analysis of antisense oligonucleotides in cell culture. Methods 2001, 23, 191-198.
18. Holt, S. E.; Norton, J. C.; Wright, W. E.; Shay, J. W. Comparison of the telomeric repeat amplification protocol (TRAP) to the new TRAP-eze telomerase detection kit. Methods Cell. Sci. 1996, 18, 237-248.
19. Henry, S.; Steker, K.; Brooks, D.; Monteith, D.; Conklin, B.; Bennett, C. F. Chemically modified oligonucleotides exhibit decreased immune stimulation in mice. J. Pharmacol. Exp. Ther. 2000, 292, 468-479.
20. Khatsenko, O.; Morgan, R.; Truong, L.; York-Defalco, C.; Sasmor, H.; Conklin, B.; Geary, R. S. Absorption of antisense oligonucleotides in rat intestine: Effect of chemistry and length. Antisense Nucleic Acid Drug Dev. 2000, 10, 35-44.
21. Baker, B. F.; Lot, S. S.; Condon, T. P.; Cheng-Flournoy, S.; Lesnik, E. A.; Sasmor, H. M.; Bennett, C. F. 2′-O-(2-methoxy)-ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells. J. Biol. Chem. 1997, 272, 11994-12000.
22. Stepowski, S. M.; Wang, M. E.; Tian, L.; Chen, W. H.; Wancewicz, E. V.; Johnston, J. F.; Bennett, C. F.; Monia, B. P. Inhibition of C-raf expression by antisense oligonucleotides extends heart allograft survival in rats. Transplantation 2000, 70, 656-661.
23. Shay, J. W.; Brasiskyte, D.; Ouellette, M.; Piatyszek, M. A.; Werbin, H.; Ying, Y.; Wright, W. E. Analysis of telomeres and telomerase. Methods Mol. Genet. 1994, 5, 263-280.
24. Duncan, V. E.; Ajmani, P. S.; Hughes, J. A. Cellular delivery is a major obstacle for oligodeoxynucleotide inhibition oftelomerase activity. Anticancer Res. 1998, 18, 4105-4108.